|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
|
23538402 |
2013 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our results showed that the formulation of BSYX had antitumor effect on endometrial cancer in vivo and in vitro and was related with FSH/PI3K/AKT/Gankyrin/HIF-<i>α</i>/cyclinD1 transduction pathway.
|
30402135 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of an endometrial cancer risk allele within a member of the PI3K/AKT signaling pathway, more commonly activated in tumors by somatic alterations, raises the possibility that well tolerated inhibitors targeting this pathway could be candidates for evaluation as chemopreventive agents in individuals at high risk of developing endometrial cancer.
|
27259051 |
2016 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
|
19917135 |
2009 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
|
22146979 |
2012 |
|
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the PI3K pathway are prevalent in endometrial cancer due to PIK3CA mutation and loss of PTEN.
|
24561032 |
2014 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is a frequently altered signalling pathway in endometrial cancer.
|
31588998 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC).
|
25624430 |
2015 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we elucidated the involvement of the up-regulation of RAS/MAPK and PI3K/AKT cascades in the pathogenesis of endometrial cancer and melanoma by analyzing the genes and molecules in these cascades.
|
16273242 |
2005 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is concluded that the PI 3-K/Akt survival pathway is involved in the regulation of COX-2 and PGE2 synthesis in human endometrial cancer cells.
|
15067356 |
2004 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results affirm the utility of systematic characterization of the cancer genome in clinically annotated specimens and suggest the particular importance of the PI3K pathway in patients who have aggressive endometrial cancer.
|
19261849 |
2009 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
13 EC cell lines were profiled for their PI3K pathway and KRAS mutational and PTEN protein status and treated with one MEK- and two PI3K- targeted inhibitors alone and in combination.
|
29426295 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HGF/Met-MAPK/PI3K pathway in endometrial cancer is activated by HGF in an autocrine manner.
|
29854314 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of PI3K/Akt signaling reversed the enhanced cell growth in Nedd4-overexpressing endometrial cancer cells.
|
26193427 |
2015 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, genetic studies evaluated the effect of inflammatory cytokines secreted by visceral adipocytes in the modulation of angiogenesis and signaling pathways such as PI3K/AKT/mTOR, that result altered in the pathogenesis of EC.
|
30338797 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in the phosphatidylinositol 3-kinase (PI3K) pathway, the central relay pathway of insulin signals, occur in the majority of endometrioid adenocarcinomas, the most common form of endometrial cancer.
|
26045339 |
2015 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
We attempt to investigate the effect of metformin on Ki-67, PI3K, p-AKT, p-S6K1, and p-4EBP1 staining in human endometrial cancer by immunohistochemical staining.
|
29182407 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
|
22075757 |
2012 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulated signaling via the phosphatidylinositol 3-kinase (PI3K) pathway is common in many types of cancer, but its clinicopathological significance in endometrial cancer remains unclear.
|
17924977 |
2007 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting key signaling components of PI3K/AKT pathway by restoring or inhibiting miRNA function holds promise as a potential therapeutic approach to suppress EMT and CSC in endometrial cancer.
|
25141911 |
2014 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
|
30569174 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, molecular analysis of endometrial cancer revealed phosphorylation-dependent oncogenic signalling in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways to be most frequently altered in type II ECs.
|
30104481 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the PI3K pathway represents a critical driver of endometrial cancer pathogenesis and a novel therapeutic target.
|
21984976 |
2011 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mammalian target of rapamycin (mTOR) pathway aberrations occur in 40% to 80% of endometrial cancer.
|
24651628 |
2014 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although molecular characterization has been reported to customize therapeutic strategies and thereby improve therapeutic outcomes in EC, none of the targeted agents investigated (antiangiogenic and mTOR/PI3K pathway inhibitor agents) have resulted in a change in clinical practice in HR-EC.
|
31176047 |
2019 |